Low cerebrospinal fluid concentrations of the nucleotide HIV reverse transcriptase inhibitor, tenofovir.
about
Recent developments in human immunodeficiency virus-1 latency researchRational development of radiopharmaceuticals for HIV-1Pharmacokinetic, Pharmacogenetic, and Other Factors Influencing CNS Penetration of AntiretroviralsTemporal Patterns and Drug Resistance in CSF Viral Escape Among ART-Experienced HIV-1 Infected AdultsMacrophages and their relevance in Human Immunodeficiency Virus Type I infection.HIV-associated neurocognitive disorders: perspective on management strategiesPreparation, characterization, and safety evaluation of poly(lactide-co-glycolide) nanoparticles for protein delivery into macrophages.Global HIV/AIDS Clinical and Translational PharmacologyCerebrospinal fluid concentrations of tenofovir and emtricitabine in the setting of HIV-1 protease inhibitor-based regimens.Protein-free efavirenz concentrations in cerebrospinal fluid and blood plasma are equivalent: applying the law of mass action to predict protein-free drug concentration.Nanoparticle-based drug delivery to improve the efficacy of antiretroviral therapy in the central nervous systemPotential effect of pharmacogenetics on maternal, fetal and infant antiretroviral drug exposure during pregnancy and breastfeeding.CSF penetration by antiretroviral drugs.Pharmacokinetics and pharmacodynamics of antiretrovirals in the central nervous system.HIV-associated Neurocognitive Disorders and Antiretroviral Therapy: Current Concepts and Controversies.Nanoformulated Antiretrovirals for Penetration of the Central Nervous System: State of the Art.Mechanisms of HIV persistence in HIV reservoirs.Population Pharmacokinetic Modeling of Tenofovir in the Genital Tract of Male HIV-Infected Patients.NRTI backbone in HIV treatment: will it remain relevant?Peroxisome proliferator-activated receptor-gamma: potential molecular therapeutic target for HIV-1-associated brain inflammation.Combination antiretroviral therapy improves cognitive performance and functional connectivity in treatment-naïve HIV-infected individuals.Discordant CSF/plasma HIV-1 RNA in patients with unexplained low-level viraemia.Central nervous system penetration of antiretroviral drugs: pharmacokinetic, pharmacodynamic and pharmacogenomic considerations.Cellular pharmacology and potency of HIV-1 nucleoside analogs in primary human macrophages.Treatment of HIV in the CNS: effects of antiretroviral therapy and the promise of non-antiretroviral therapeutics.Risk for Speech and Language Impairments in Pre-school Aged HIV-Exposed Uninfected Children with in utero Combination Antiretroviral Exposure.CNS penetration of ART in HIV-infected children.Symptomatic cerebrospinal fluid HIV-1 escape with no resistance-associated mutations following low-level plasma viremia.Pharmacogenetics-based population pharmacokinetic analysis of tenofovir in Thai HIV-infected patients.Harnessing nanostructured systems for improved treatment and prevention of HIV disease
P2860
Q27013114-D6607A56-DDDB-4021-98C1-EA54C3406A2DQ27022025-A68B0989-9CE8-4300-9CF2-47D163D20B40Q28069383-8C8EA2D0-9D50-4B47-BE83-172FFD2F2D4AQ33750994-B97DB21C-24D6-4E18-94AD-A49C1AFE1C37Q34303855-509FB9EA-AB5E-4E07-B090-A25A6932B1A0Q34652590-92DE5868-C145-47C6-B10F-6400DA15921CQ36111190-F97767E8-FCAF-4D6F-8F08-100489372358Q36125023-8121E16A-5949-450F-B58A-554DE97D0330Q36553973-44F61A88-D230-42B2-9F61-D9EE2191A11DQ36667153-8497B971-3550-482E-A790-7ADD199E9CE7Q37698620-BA1FC52B-1AB1-4419-96DD-732F92F0D8ABQ38051400-74B8D5B1-F94A-48BC-9AFE-CD54FF051EAAQ38060571-7503313A-537F-4693-9EFF-35458B970882Q38247035-4FCF14F4-4FE4-4824-9F2D-371D891EE120Q38444808-F162715B-5257-4D8E-A114-C6E2B22BA686Q39004638-E647F411-83C5-4FC2-927E-C49F5CD96D3DQ39106572-0BC7F5C7-BF2B-48E5-9AE3-A6BBDE1050C8Q39107383-37FA2434-6971-4E85-B0ED-0C619651947EQ39533858-E615FFAA-C509-4700-8A49-07BE96D064ADQ40050469-C33F2F80-26D0-472D-B298-EE0435278A1EQ40100880-BE08BCFD-999F-4B3A-A604-27D91C5D9825Q40668682-7B1D2480-C386-4D0E-9215-52F26C53E393Q41208022-B4DDF546-EEEB-4184-BA32-CC10D7AFDF14Q41451997-6E8E1E61-8A19-4A39-9145-A395731B731EQ42203691-76F565A8-2643-4E38-A0D0-2B8F63FBD44AQ47185150-7BF8FD01-1865-48F4-9698-57B35F9FDD44Q47416079-876FA073-6782-4CC4-8524-BFEACA158E1DQ47564644-D4CFF441-21BB-40EB-AC61-D4C584C02587Q47633560-CFD4006D-2867-4036-B501-0A861FA7B293Q56992437-610177B7-EBAB-48A6-88C3-F0397DA69C02
P2860
Low cerebrospinal fluid concentrations of the nucleotide HIV reverse transcriptase inhibitor, tenofovir.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Low cerebrospinal fluid concen ...... criptase inhibitor, tenofovir.
@ast
Low cerebrospinal fluid concen ...... criptase inhibitor, tenofovir.
@en
type
label
Low cerebrospinal fluid concen ...... criptase inhibitor, tenofovir.
@ast
Low cerebrospinal fluid concen ...... criptase inhibitor, tenofovir.
@en
prefLabel
Low cerebrospinal fluid concen ...... criptase inhibitor, tenofovir.
@ast
Low cerebrospinal fluid concen ...... criptase inhibitor, tenofovir.
@en
P2093
P2860
P50
P1476
Low cerebrospinal fluid concen ...... criptase inhibitor, tenofovir.
@en
P2093
Ann C Collier
Benjamin B Gelman
Brookie M Best
CHARTER Study Group
Christina M Marra
David B Clifford
David M Simpson
Edmund V Capparelli
J Allen McCutchan
Justin C McArthur
P2860
P304
P356
10.1097/QAI.0B013E318247EC54
P407
P577
2012-04-01T00:00:00Z